MGNX · Macrogenics Inc · Webcasts, Transcripts & Audio
$1.99
-0.07 (-3.17%)
At close · Nov 18
Return incl. dividend (before tax)
Q2 2024 earnings call transcript
Market Cap
$131.01M
Shares
63.91M
Volume · Nov 18
117.28K
Avg daily vol (3M)
709.77K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Macrogenics Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Macrogenics Inc (MGNX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q1
2026-05-20
Macrogenics Inc (MGNX) Q1 2026 Earnings Call
Revenue
$20.77M
▲ 57.5% YoY Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Macrogenics Inc (MGNX) Q1 2025 Earnings Call
Revenue
$13.19M
▲ 44.9% YoY Diluted EPS
$-0.65
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Macrogenics Inc (MGNX) Q4 2024 Earnings Call
Revenue
$19.35M*
▲ 80.5% YoY Gross margin
98.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Macrogenics Inc (MGNX) Q3 2024 Earnings Call
Revenue
$110.71M
▲ 964.8% YoY Diluted EPS
$0.90
▲ 221.4% YoY Gross margin
99.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Macrogenics Inc (MGNX) Q2 2024 Earnings Call Transcript
Positive tone
TAMARACK Phase II and vobra duo in mCRPC
B7-H3 pipeline strategy (MGC026, enoblituzumab)
R&D expense growth
Revenue
$10.80M
▼ 17.8% YoY Diluted EPS
$-0.89
▼ 196.7% YoY Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Macrogenics Inc (MGNX) Q1 2024 Earnings Call Transcript
Positive tone
TAMARACK Phase II study (vobramitamab duocarmazine in mCRPC)
Dose selection between 2 mg/kg and 2.7 mg/kg
Durability / response confirmation
Revenue
$9.10M
▼ 62.8% YoY Diluted EPS
$-0.84
Gross margin
97.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Macrogenics Inc (MGNX) Q4 2023 Earnings Call Transcript
Positive tone
Vobramitamab duocarmazine (vobra duo) / TAMARACK Phase 2
ADC pipeline expansion
Lorigerlimab / LORIKEET study
Revenue
$10.72M*
▼ 85.3% YoY Gross margin
98.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Macrogenics Inc (MGNX) Q3 2023 Earnings Call Transcript
Revenue
$10.40M
▼ 75.1% YoY Diluted EPS
$0.28
Gross margin
99.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Macrogenics Inc (MGNX) Q2 2023 Earnings Call Transcript
Revenue
$13.14M
▼ 49.5% YoY Diluted EPS
$0.92
Gross margin
98.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Macrogenics Inc (MGNX) Q1 2023 Earnings Call Transcript
Revenue
$24.50M
▲ 120.7% YoY Diluted EPS
$-0.61
Gross margin
99.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
Macrogenics Inc (MGNX) Q4 2022 Earnings Call Transcript
Revenue
$73.10M*
▲ 416.7% YoY Gross margin
99.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Macrogenics Inc (MGNX) Q3 2022 Earnings Call Transcript
Revenue
$41.73M
▲ 166.5% YoY Diluted EPS
$-0.40
Gross margin
92.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Macrogenics Inc (MGNX) Q2 2022 Earnings Call Transcript
Revenue
$26.01M
▼ 15.4% YoY Diluted EPS
$-0.67
Gross margin
99.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Macrogenics Inc (MGNX) Q1 2022 Earnings Call Transcript
Revenue
$11.10M
▼ 34.2% YoY Diluted EPS
$-1.08
Gross margin
99.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Macrogenics Inc (MGNX) Q4 2021 Earnings Call Transcript
Revenue
$14.15M*
▼ 73.2% YoY Gross margin
93.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Macrogenics Inc (MGNX) Q3 2021 Earnings Call Transcript
Revenue
$15.66M
▼ 14.2% YoY Diluted EPS
$-0.86
Gross margin
89.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Macrogenics Inc (MGNX) Q2 2021 Earnings Call Transcript
Revenue
$30.76M
▲ 51.8% YoY Diluted EPS
$-0.66
Gross margin
99.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Macrogenics Inc (MGNX) Q1 2021 Earnings Call Transcript
Revenue
$16.88M
▲ 23.4% YoY Diluted EPS
$-0.90
Gross margin
99.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Macrogenics Inc (MGNX) Q4 2020 Earnings Call Transcript
Revenue
$52.69M*
▲ 109.2% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Macrogenics Inc (MGNX) Q3 2020 Earnings Call Transcript
Revenue
$18.25M
▼ 2.6% YoY Diluted EPS
$-0.66
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Macrogenics Inc (MGNX) Q2 2020 Earnings Call Transcript
Revenue
$20.26M
▲ 91.2% YoY Diluted EPS
$-0.94
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Macrogenics Inc (MGNX) Q1 2020 Earnings Call Transcript
Revenue
$13.68M
▲ 41.6% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 webcasts
Key facts
CIK
1125345
CUSIP
556099109
13F (30d)
143 filings
127 filers
Visit website
Investor relations